Clinical trial on Psoriasis

Evaluation of Safety and efficacy of two different unani compound formulations UNIM 401(O) and 403(L) in cases of Daus Sadaf (Psoriasis)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/05/013636

Enrollment

120

Registered

2018-05-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Psoriasis

Interventions

Intervention1: UNIM 401(Oral) and UNIM 403(local application): UNIM 401 500 mg capsules 2 BD UNIM 403 oil applied topically Duration of treatment is 6 months Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: Apparent psoriatic lesions of the body.

Exclusion criteria

Exclusion criteria: 1. Patients with psoriatic arthritis 2. Patients suffering with other skin diseases 3. Serious systemic diseases 4. Pregnant and lactating mothers 5. Patient unsure about attending treatment schedule regularly and those who do not have a suitable place for sun exposure.

Design outcomes

Primary

Measure	Time frame
Clearance of psoriasis in terms of PASI scoring or 6 months of treatment which ever is earlier.Timepoint: Baseline, 1st month, 2nd, 3rd, 4th, 5th, 6th	—

Secondary

Measure	Time frame
Assessment of Safety in terms of LFT and RFTTimepoint: Baseline, Monthly follow ups for 6 months	—

Countries

India

Contacts

Public ContactDr Syed Gulnawaz Ahmed

Central Research Institute of Unani Medicine

drmunawwar@yahoo.com9030168455

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026